{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:05Z","timestamp":1789609205229,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,9]],"date-time":"2014-09-09T00:00:00Z","timestamp":1410220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1007\/s12035-014-8887-2","type":"journal-article","created":{"date-parts":[[2014,9,8]],"date-time":"2014-09-08T02:12:24Z","timestamp":1410142344000},"page":"456-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Synaptic Pathophysiology and Treatment of Lambert-Eaton Myasthenic Syndrome"],"prefix":"10.1007","volume":"52","author":[{"given":"Tyler B.","family":"Tarr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wipf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Meriney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,9]]},"reference":[{"key":"8887_CR1","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1152\/physiol.00014.2004","volume":"19","author":"RG Zhai","year":"2004","unstructured":"Zhai RG, Bellen HJ (2004) The architecture of the active zone in the presynaptic nerve terminal. Physiology (Bethesda) 19:262\u2013270","journal-title":"Physiology (Bethesda)"},{"key":"8887_CR2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0301-0082(00)00055-1","volume":"64","author":"SJ Wood","year":"2001","unstructured":"Wood SJ, Slater CR (2001) Safety factor at the neuromuscular junction. Prog Neurobiol 64:393\u2013429","journal-title":"Prog Neurobiol"},{"key":"8887_CR3","first-page":"612","volume":"187","author":"EH Lambert","year":"1956","unstructured":"Lambert EH, Eaton LM, Rooke ED (1956) Defect of neuromuscular conduction associated with malignant neoplasms. Am J Physiol 187:612\u2013613","journal-title":"Am J Physiol"},{"key":"8887_CR4","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/0166-2236(89)90109-4","volume":"12","author":"A Vincent","year":"1989","unstructured":"Vincent A, Lang B, Newsom-Davis J (1989) Autoimmunity to the voltage-gated calcium channel underlies the Lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci 12:496\u2013502","journal-title":"Trends Neurosci"},{"key":"8887_CR5","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/ana.410400510","volume":"40","author":"SD Meriney","year":"1996","unstructured":"Meriney SD, Hulsizer SC, Lennon VA, Grinnell AD (1996) Lambert-Eaton myasthenic syndrome immunoglobulins react with multiple types of calcium channels in small-cell lung carcinoma. Ann Neurol 40:739\u2013749","journal-title":"Ann Neurol"},{"key":"8887_CR6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1093\/brain\/111.3.577","volume":"111","author":"JH O'Neill","year":"1988","unstructured":"O'Neill JH, Murray NM, Newsom-Davis J (1988) The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 111:577\u2013596","journal-title":"Brain"},{"key":"8887_CR7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/j.1749-6632.2012.06769.x","volume":"1275","author":"P Maddison","year":"2012","unstructured":"Maddison P (2012) Treatment in Lambert-Eaton myasthenic syndrome. Ann N Y Acad Sci 1275:78\u201384","journal-title":"Ann N Y Acad Sci"},{"key":"8887_CR8","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s11940-012-0213-6","volume":"15","author":"A Sonderen van","year":"2013","unstructured":"van Sonderen A, Wirtz PW, Verschuuren JJ, Titulaer MJ (2013) Paraneoplastic syndromes of the neuromuscular junction: therapeutic options in myasthenia gravis, Lambert-Eaton myasthenic syndrome, and neuromyotonia. Curr Treat Options Neurol 15:224\u2013239","journal-title":"Curr Treat Options Neurol"},{"key":"8887_CR9","volume-title":"The release of neural transmitter substances","author":"B Katz","year":"1969","unstructured":"Katz B (1969) The release of neural transmitter substances. Liverpool Univ, Press, Liverpool"},{"key":"8887_CR10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/314164a0","volume":"314","author":"R Hennig","year":"1985","unstructured":"Hennig R, Lomo T (1985) Firing patterns of motor units in normal rats. Nature 314:164\u2013166","journal-title":"Nature"},{"key":"8887_CR11","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/cne.21975","volume":"513","author":"S Nagwaney","year":"2009","unstructured":"Nagwaney S, Harlow ML, Jung JH, Szule JA, Ress D, Xu J, Marshall RM, McMahan UJ (2009) Macromolecular connections of active zone material to docked synaptic vesicles and presynaptic membrane at neuromuscular junctions of mouse. J Comp Neurol 513:457\u2013468","journal-title":"J Comp Neurol"},{"key":"8887_CR12","doi-asserted-by":"crossref","first-page":"7636","DOI":"10.1073\/pnas.80.24.7636","volume":"80","author":"H Fukunaga","year":"1983","unstructured":"Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A (1983) Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sci U S A 80:7636\u20137640","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8887_CR13","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1523\/JNEUROSCI.4663-10.2011","volume":"31","author":"R Ruiz","year":"2011","unstructured":"Ruiz R, Cano R, Casanas JJ, Gaffield MA, Betz WJ, Tabares L (2011) Active zones and the readily releasable pool of synaptic vesicles at the neuromuscular junction of the mouse. J Neurosci 31:2000\u20132008","journal-title":"J Neurosci"},{"key":"8887_CR14","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/cne.22764","volume":"520","author":"J Chen","year":"2012","unstructured":"Chen J, Mizushige T, Nishimune H (2012) Active zone density is conserved during synaptic growth but impaired in aged mice. J Comp Neurol 520:434\u2013452","journal-title":"J Comp Neurol"},{"key":"8887_CR15","doi-asserted-by":"crossref","first-page":"10559","DOI":"10.1523\/JNEUROSCI.4629-12.2013","volume":"33","author":"TB Tarr","year":"2013","unstructured":"Tarr TB, Malick W, Liang M, Valdomir G, Frasso M, Lacomis D, Reddel SW, Garcia-Ocano A, Wipf P, Meriney SD (2013) Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci 33:10559\u201310567","journal-title":"J Neurosci"},{"key":"8887_CR16","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.tins.2012.09.009","volume":"36","author":"TB Tarr","year":"2013","unstructured":"Tarr TB, Dittrich M, Meriney SD (2013) Are unreliable release mechanisms conserved from NMJ to CNS? Trends Neurosci 36:14\u201322","journal-title":"Trends Neurosci"},{"key":"8887_CR17","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1113\/jphysiol.2012.248625","volume":"591","author":"SD Meriney","year":"2013","unstructured":"Meriney SD, Dittrich M (2013) Organization and function of transmitter release sites at the neuromuscular junction. J Physiol 591:3159\u20133165","journal-title":"J Physiol"},{"key":"8887_CR18","doi-asserted-by":"crossref","first-page":"11268","DOI":"10.1523\/JNEUROSCI.1394-11.2011","volume":"31","author":"F Luo","year":"2011","unstructured":"Luo F, Dittrich M, Stiles JR, Meriney SD (2011) Single-pixel optical fluctuation analysis of calcium channel function in active zones of motor nerve terminals. J Neurosci 31:11268\u201311281","journal-title":"J Neurosci"},{"key":"8887_CR19","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s00415-003-1063-7","volume":"250","author":"PW Wirtz","year":"2003","unstructured":"Wirtz PW, Nijnuis MG, Sotodeh M, Willems LN, Brahim JJ, Putter H, Wintzen AR, Verschuuren JJ, Dutch Myasthenia Study G (2003) The epidemiology of myasthenia gravis, Lambert-Eaton myasthenic syndrome and their associated tumours in the northern part of the province of South Holland. J Neurol 250:698\u2013701","journal-title":"J Neurol"},{"key":"8887_CR20","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1200\/JCO.2010.32.0440","volume":"29","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Maddison P, Sont JK, Wirtz PW, Hilton-Jones D, Klooster R, Willcox N, Potman M, Sillevis Smitt PA, Kuks JB, Roep BO, Vincent A, van der Maarel SM, van Dijk JG, Lang B, Verschuuren JJ (2011) Clinical Dutch-English Lambert-Eaton myasthenic syndrome (LEMS) tumor association prediction score accurately predicts small-cell lung cancer in the LEMS. J Clin Oncol 29:902\u2013908","journal-title":"J Clin Oncol"},{"key":"8887_CR21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1196\/annals.1405.030","volume":"1132","author":"MJ Titulaer","year":"2008","unstructured":"Titulaer MJ, Verschuuren JJ (2008) Lambert-Eaton myasthenic syndrome: tumor versus nontumor forms. Ann N Y Acad Sci 1132:129\u2013134","journal-title":"Ann N Y Acad Sci"},{"key":"8887_CR22","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S1474-4422(11)70245-9","volume":"10","author":"MJ Titulaer","year":"2011","unstructured":"Titulaer MJ, Lang B, Verschuuren JJ (2011) Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol 10:1098\u20131107","journal-title":"Lancet Neurol"},{"key":"8887_CR23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJM199506013322203","volume":"332","author":"VA Lennon","year":"1995","unstructured":"Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH (1995) Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 332:1467\u20131474","journal-title":"N Engl J Med"},{"key":"8887_CR24","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/317737a0","volume":"317","author":"A Roberts","year":"1985","unstructured":"Roberts A, Perera S, Lang B, Vincent A, Newsom-Davis J (1985) Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line. Nature 317:737\u2013739","journal-title":"Nature"},{"key":"8887_CR25","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1113\/jphysiol.2002.021048","volume":"543","author":"MT Flink","year":"2002","unstructured":"Flink MT, Atchison WD (2002) Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission. J Physiol 543:567\u2013576","journal-title":"J Physiol"},{"key":"8887_CR26","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/mus.20672","volume":"35","author":"SJ Oh","year":"2007","unstructured":"Oh SJ, Hatanaka Y, Claussen GC, Sher E (2007) Electrophysiological differences in seropositive and seronegative Lambert-Eaton myasthenic syndrome. Muscle Nerve 35:178\u2013183","journal-title":"Muscle Nerve"},{"key":"8887_CR27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1113\/jphysiol.1995.sp020865","volume":"487","author":"DO Smith","year":"1995","unstructured":"Smith DO, Conklin MW, Jensen PJ, Atchison WD (1995) Decreased calcium currents in motor nerve terminals of mice with Lambert-Eaton myasthenic syndrome. J Physiol 487:115\u2013123","journal-title":"J Physiol"},{"key":"8887_CR28","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1073\/pnas.0437991100","volume":"100","author":"FJ Urbano","year":"2003","unstructured":"Urbano FJ, Piedras-Renteria ES, Jun K, Shin HS, Uchitel OD, Tsien RW (2003) Altered properties of quantal neurotransmitter release at endplates of mice lacking P\/Q-type Ca2+ channels. Proc Natl Acad Sci U S A 100:3491\u20133496","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8887_CR29","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/nature03112","volume":"432","author":"H Nishimune","year":"2004","unstructured":"Nishimune H, Sanes JR, Carlson SS (2004) A synaptic laminin-calcium channel interaction organizes active zones in motor nerve terminals. Nature 432:580\u2013587","journal-title":"Nature"},{"key":"8887_CR30","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1523\/JNEUROSCI.3771-10.2011","volume":"31","author":"J Chen","year":"2011","unstructured":"Chen J, Billings SE, Nishimune H (2011) Calcium channels link the muscle-derived synapse organizer laminin beta2 to Bassoon and CAST\/Erc2 to organize presynaptic active zones. J Neurosci 31:512\u2013525","journal-title":"J Neurosci"},{"key":"8887_CR31","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/nn.3137","volume":"15","author":"N Holderith","year":"2012","unstructured":"Holderith N, Lorincz A, Katona G, Rozsa B, Kulik A, Watanabe M, Nusser Z (2012) Release probability of hippocampal glutamatergic terminals scales with the size of the active zone. Nat Neurosci 15:988\u2013997","journal-title":"Nat Neurosci"},{"key":"8887_CR32","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nn.3129","volume":"15","author":"J Sheng","year":"2012","unstructured":"Sheng J, He L, Zheng H, Xue L, Luo F, Shin W, Sun T, Kuner T, Yue DT, Wu LG (2012) Calcium-channel number critically influences synaptic strength and plasticity at the active zone. Nat Neurosci 15:998\u20131006","journal-title":"Nat Neurosci"},{"key":"8887_CR33","doi-asserted-by":"crossref","first-page":"12192","DOI":"10.1523\/JNEUROSCI.0752-12.2012","volume":"32","author":"S Tom Dieck","year":"2012","unstructured":"Tom Dieck S, Specht D, Strenzke N, Hida Y, Krishnamoorthy V, Schmidt KF, Inoue E, Ishizaki H, Tanaka-Okamoto M, Miyoshi J, Hagiwara A, Brandstatter JH, Lowel S, Gollisch T, Ohtsuka T, Moser T (2012) Deletion of the presynaptic scaffold CAST reduces active zone size in rod photoreceptors and impairs visual processing. J Neurosci 32:12192\u201312203","journal-title":"J Neurosci"},{"key":"8887_CR34","doi-asserted-by":"crossref","first-page":"19590","DOI":"10.1523\/JNEUROSCI.3396-13.2013","volume":"33","author":"M Shahidullah","year":"2013","unstructured":"Shahidullah M, Le Marchand SJ, Fei H, Zhang J, Pandey UB, Dalva MB, Pasinelli P, Levitan IB (2013) Defects in synapse structure and function precede motor neuron degeneration in Drosophila models of FUS-related ALS. J Neurosci 33:19590\u201319598","journal-title":"J Neurosci"},{"key":"8887_CR35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1212\/WNL.44.2.334","volume":"44","author":"I Johnston","year":"1994","unstructured":"Johnston I, Lang B, Leys K, Newsom-Davis J (1994) Heterogeneity of calcium channel autoantibodies detected using a small-cell lung cancer line derived from a Lambert-Eaton myasthenic syndrome patient. Neurology 44:334\u2013338","journal-title":"Neurology"},{"key":"8887_CR36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-510X(96)05303-8","volume":"147","author":"M Motomura","year":"1997","unstructured":"Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J (1997) Incidence of serum anti-P\/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 147:35\u201342","journal-title":"J Neurol Sci"},{"key":"8887_CR37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/ana.410420204","volume":"42","author":"SA Waterman","year":"1997","unstructured":"Waterman SA, Lang B, Newsom-Davis J (1997) Effect of Lambert-Eaton myasthenic syndrome antibodies on autonomic neurons in the mouse. Ann Neurol 42:147\u2013156","journal-title":"Ann Neurol"},{"key":"8887_CR38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jneuroim.2008.04.040","volume":"201\u2013202","author":"M Takamori","year":"2008","unstructured":"Takamori M (2008) Lambert\u2013Eaton myasthenic syndrome: search for alternative autoimmune targets and possible compensatory mechanisms based on presynaptic calcium homeostasis. J Neuroimmunol 201\u2013202:145\u2013152","journal-title":"J Neuroimmunol"},{"key":"8887_CR39","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neuron.2013.10.022","volume":"80","author":"TC S\u00fcdhof","year":"2013","unstructured":"S\u00fcdhof TC (2013) Neurotransmitter release: the last millisecond in the life of a synaptic vesicle. Neuron 80:675\u2013690","journal-title":"Neuron"},{"key":"8887_CR40","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1111\/j.1460-9568.2006.04753.x","volume":"23","author":"MM Santafe","year":"2006","unstructured":"Santafe MM, Lanuza MA, Garcia N, Tomas J (2006) Muscarinic autoreceptors modulate transmitter release through protein kinase C and protein kinase A in the rat motor nerve terminal. Eur J Neurosci 23:2048\u20132056","journal-title":"Eur J Neurosci"},{"key":"8887_CR41","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1212\/01.WNL.0000037485.56217.5F","volume":"59","author":"YK Nakao","year":"2002","unstructured":"Nakao YK, Motomura M, Fukudome T, Fukuda T, Shiraishi H, Yoshimura T, Tsujihata M, Eguchi K (2002) Seronegative Lambert-Eaton myasthenic syndrome: study of 110 Japanese patients. Neurology 59:1773\u20131775","journal-title":"Neurology"},{"key":"8887_CR42","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1212\/WNL.50.1.88","volume":"50","author":"P O'Suilleabhain","year":"1998","unstructured":"O'Suilleabhain P, Low PA, Lennon VA (1998) Autonomic dysfunction in the Lambert-Eaton myasthenic syndrome: serologic and clinical correlates. Neurology 50:88\u201393","journal-title":"Neurology"},{"key":"8887_CR43","doi-asserted-by":"crossref","unstructured":"Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome (2001) Muscle Nerve 24:1239\u20131247","DOI":"10.1002\/mus.1140"},{"key":"8887_CR44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1002\/mus.20389","volume":"32","author":"SJ Oh","year":"2005","unstructured":"Oh SJ, Kurokawa K, Claussen GC, Ryan HF Jr (2005) Electrophysiological diagnostic criteria of Lambert-Eaton myasthenic syndrome. Muscle Nerve 32:515\u2013520","journal-title":"Muscle Nerve"},{"key":"8887_CR45","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/brain\/120.8.1279","volume":"120","author":"WP Mason","year":"1997","unstructured":"Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, Antoine JC, Rosenblum MK, Rosenfeld MR, Newsom-Davis J, Posner JB, Dalmau J (1997) Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120:1279\u20131300","journal-title":"Brain"},{"key":"8887_CR46","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3816\/CLC.2006.n.008","volume":"7","author":"S Wang","year":"2006","unstructured":"Wang S, Bruzzi J, Rodriguez-Garza VP, Komaki RR (2006) Lambert-eaton myasthenic syndrome in a patient with small-cell lung cancer. Clin Lung Cancer 7:282\u2013284","journal-title":"Clin Lung Cancer"},{"key":"8887_CR47","first-page":"341","volume":"7","author":"S Lindquist","year":"2011","unstructured":"Lindquist S, Stangel M (2011) Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 7:341\u2013349","journal-title":"Neuropsychiatr Dis Treat"},{"key":"8887_CR48","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1517\/14656566.7.10.1323","volume":"7","author":"JJ Verschuuren","year":"2006","unstructured":"Verschuuren JJ, Wirtz PW, Titulaer MJ, Willems LN, van Gerven J (2006) Available treatment options for the management of Lambert-Eaton myasthenic syndrome. Expert Opin Pharmacother 7:1323\u20131336","journal-title":"Expert Opin Pharmacother"},{"key":"8887_CR49","volume":"2","author":"M Keogh","year":"2011","unstructured":"Keogh M, Sedehizadeh S, Maddison P (2011) Treatment for Lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev 2, CD003279","journal-title":"Cochrane Database Syst Rev"},{"key":"8887_CR50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0006-3495(78)85503-9","volume":"22","author":"GE Kirsch","year":"1978","unstructured":"Kirsch GE, Narahashi T (1978) 3,4-diaminopyridine. A potent new potassium channel blocker. Biophys J 22:507\u2013512","journal-title":"Biophys J"},{"key":"8887_CR51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/WNF.0b013e31825a68c5","volume":"35","author":"S Sedehizadeh","year":"2012","unstructured":"Sedehizadeh S, Keogh M, Maddison P (2012) The use of aminopyridines in neurological disorders. Clin Neuropharmacol 35:191\u2013200","journal-title":"Clin Neuropharmacol"},{"key":"8887_CR52","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/clpt.2009.35","volume":"86","author":"PW Wirtz","year":"2009","unstructured":"Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, Titulaer MJ, Tjaden UR, den Hartigh J, van Gerven JM (2009) Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of Lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther 86:44\u201348","journal-title":"Clin Pharmacol Ther"},{"key":"8887_CR53","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1002\/mus.21422","volume":"40","author":"SJ Oh","year":"2009","unstructured":"Oh SJ, Claussen GG, Hatanaka Y, Morgan MB (2009) Diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve 40:795\u2013800","journal-title":"Muscle Nerve"},{"key":"8887_CR54","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/WNL.54.3.603","volume":"54","author":"DB Sanders","year":"2000","unstructured":"Sanders DB, Massey JM, Sanders LL, Edwards LJ (2000) A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54:603\u2013607","journal-title":"Neurology"},{"key":"8887_CR55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0006-8993(97)01516-3","volume":"789","author":"F Miralles","year":"1998","unstructured":"Miralles F, Solsona C (1998) 3,4-Diaminopyridine-induced impairment in frog motor nerve terminal response to high frequency stimulation. Brain Res 789:239\u2013244","journal-title":"Brain Res"},{"key":"8887_CR56","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S0022-3565(25)22023-7","volume":"227","author":"RH Thomsen","year":"1983","unstructured":"Thomsen RH, Wilson DF (1983) Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. J Pharmacol Exp Ther 227:260\u2013265","journal-title":"J Pharmacol Exp Ther"},{"key":"8887_CR57","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1212\/WNL.34.4.480","volume":"34","author":"J Newsom-Davis","year":"1984","unstructured":"Newsom-Davis J, Murray NM (1984) Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome. Neurology 34:480\u2013485","journal-title":"Neurology"},{"key":"8887_CR58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/jnnp.70.2.212","volume":"70","author":"P Maddison","year":"2001","unstructured":"Maddison P, Lang B, Mills K, Newsom-Davis J (2001) Long term outcome in Lambert-Eaton myasthenic syndrome without lung cancer. J Neurol Neurosurg Psychiatry 70:212\u2013217","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"8887_CR59","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","volume":"50","author":"J Palace","year":"1998","unstructured":"Palace J, Newsom-Davis J, Lecky B (1998) A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50:1778\u20131783","journal-title":"Neurology"},{"key":"8887_CR60","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1749-6632.1998.tb11024.x","volume":"841","author":"RW Tim","year":"1998","unstructured":"Tim RW, Massey JM, Sanders DB (1998) Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. Ann N Y Acad Sci 841:823\u2013826","journal-title":"Ann N Y Acad Sci"},{"key":"8887_CR61","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1212\/WNL.54.11.2176","volume":"54","author":"RW Tim","year":"2000","unstructured":"Tim RW, Massey JM, Sanders DB (2000) Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 54:2176\u20132178","journal-title":"Neurology"},{"key":"8887_CR62","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1212\/WNL.47.3.678","volume":"47","author":"PG Bain","year":"1996","unstructured":"Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, Vincent A, Lang B (1996) Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology 47:678\u2013683","journal-title":"Neurology"},{"key":"8887_CR63","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1212\/WNL.42.7.1422","volume":"42","author":"SJ Bird","year":"1992","unstructured":"Bird SJ (1992) Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology 42:1422\u20131423","journal-title":"Neurology"},{"key":"8887_CR64","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/mus.880170919","volume":"17","author":"H Takano","year":"1994","unstructured":"Takano H, Tanaka M, Koike R, Nagai H, Arakawa M, Tsuji S (1994) Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 17:1073\u20131075","journal-title":"Muscle Nerve"},{"key":"8887_CR65","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/(SICI)1097-4598(199706)20:6<674::AID-MUS3>3.0.CO;2-5","volume":"20","author":"S Muchnik","year":"1997","unstructured":"Muchnik S, Losavio AS, Vidal A, Cura L, Mazia C (1997) Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 20:674\u2013678","journal-title":"Muscle Nerve"},{"key":"8887_CR66","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1007\/s11940-012-0210-9","volume":"15","author":"JC Antoine","year":"2013","unstructured":"Antoine JC, Camdessanche JP (2013) Treatment options in paraneoplastic disorders of the peripheral nervous system. Curr Treat Options Neurol 15:210\u2013223","journal-title":"Curr Treat Options Neurol"},{"key":"8887_CR67","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1021\/ml3002083","volume":"3","author":"M Liang","year":"2012","unstructured":"Liang M, Tarr TB, Bravo-Altamirano K, Valdomir G, Rensch G, Swanson L, DeStefino NR, Mazzarisi CM, Olszewski RA, Wilson GM, Meriney SD, Wipf P (2012) Synthesis and biological evaluation of a selective N- and P\/Q-type calcium channel agonist. ACS Med Chem Lett 3:985\u2013990","journal-title":"ACS Med Chem Lett"},{"key":"8887_CR68","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1113\/jphysiol.2001.013376","volume":"540","author":"Z Yan","year":"2002","unstructured":"Yan Z, Chi P, Bibb JA, Ryan TA, Greengard P (2002) Roscovitine: a novel regulator of P\/Q-type calcium channels and transmitter release in central neurons. J Physiol 540:761\u2013770","journal-title":"J Physiol"},{"key":"8887_CR69","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.neuroscience.2010.02.041","volume":"167","author":"NR DeStefino","year":"2010","unstructured":"DeStefino NR, Pilato AA, Dittrich M, Cherry SV, Cho S, Stiles JR, Meriney SD (2010) (R)-roscovitine prolongs the mean open time of unitary N-type calcium channel currents. Neuroscience 167:838\u2013849","journal-title":"Neuroscience"},{"key":"8887_CR70","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1113\/jphysiol.2014.276493","volume":"592","author":"TB Tarr","year":"2014","unstructured":"Tarr TB, Lacomis D, Reddel SW, Liang M, Valdomir G, Frasso M, Wipf P, Meriney SD (2014) Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K channel blocker and a Ca2+ channel agonist. J Physiol 592:3687\u20133696","journal-title":"J Physiol"},{"key":"8887_CR71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1113\/jphysiol.1991.sp018550","volume":"436","author":"M Dorlochter","year":"1991","unstructured":"Dorlochter M, Irintchev A, Brinkers M, Wernig A (1991) Effects of enhanced activity on synaptic transmission in mouse extensor digitorum longus muscle. J Physiol 436:283\u2013292","journal-title":"J Physiol"},{"key":"8887_CR72","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1523\/JNEUROSCI.4434-08.2009","volume":"29","author":"L Kong","year":"2009","unstructured":"Kong L, Wang X, Choe DW, Polley M, Burnett BG, Bosch-Marce M, Griffin JW, Rich MM, Sumner CJ (2009) Impaired synaptic vesicle release and immaturity of neuromuscular junctions in spinal muscular atrophy mice. J Neurosci 29:842\u2013851","journal-title":"J Neurosci"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-014-8887-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-014-8887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-014-8887-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-014-8887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T14:26:14Z","timestamp":1746368774000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-014-8887-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,9]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["8887"],"URL":"https:\/\/doi.org\/10.1007\/s12035-014-8887-2","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,9]]}}}